Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.

A woman is frustrated with her hair loss and the slow, ineffective healthcare system in Canada. She has tried treatments like minoxidil, doxycycline, and kenalog injections, but continues to experience painful inflammation and hair loss.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.

Finasteride and dutasteride are still available in the EU, with a warning about potential suicidal thoughts. The benefits of these treatments are deemed greater than the risks.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

A man with thick, white hair is admired for his genetics, leading to discussions about hair loss and the preference for white hair over balding. Some speculate about the use of treatments like finasteride.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

Availability of topical anti-androgens, especially RU58841, in Australia. Issues with customs seizures and lack of credible local sources.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation is a humorous and hopeful prayer for the effectiveness of finasteride in combating hair loss. Participants express gratitude and support for the treatment.

A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.

User seeks reputable international finasteride seller due to dermatologists refusing prescription. Dermatologists suggested PRP or exosomes instead.

A user shared a positive experience about receiving free finasteride from their dermatologist. Others discussed the varying costs of finasteride in different countries.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.